8-K: Hillenbrand Sells Majority Stake in Milacron Injection Molding Business Amidst Q1 2025 Results

Hillenbrand reports Q1 2025 results, announces the sale of a majority stake in its Milacron injection molding and extrusion business to Bain Capital, and updates its full-year guidance.

Summary

• Hillenbrand reported its fiscal first quarter 2025 results, with revenue of $707 million, a 9% decrease compared to the prior year.
• GAAP EPS decreased to $0.09 from $0.24, while adjusted EPS decreased to $0.56 from $0.69.
• The company has entered into a definitive agreement to sell a majority stake in its Milacron injection molding and extrusion business to an affiliate of Bain Capital for $287 million.
• Net proceeds after tax are expected to be approximately $250 million, which will be used for debt paydown.
• Hillenbrand is updating its full-year guidance to reflect the Milacron transaction, maintaining the previous outlook for the remaining businesses with adjusted EPS of $2.45 $2.80.
• Q2 adjusted EPS is expected to be $0.53 to $0.58.
• Total backlog decreased 15% to $1.82 billion, primarily driven by lower order intake in the Advanced Process Solutions segment, while MTS backlog increased 1%.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is selling a business unit and experiencing revenue and earnings declines, they are also focusing on higher-growth areas and using proceeds to reduce debt. The outlook is mixed, with updated guidance reflecting the divestiture.

Positives

• The sale of Milacron is expected to enhance Hillenbrand's overall margin profile and focus the portfolio on less cyclical, higher-growth opportunities.
• Net proceeds from the Milacron sale will be used for debt paydown.
• The company is maintaining its previous outlook for the remaining businesses.
• Cash flow from operations improved by $13 million year-over-year.
• Liquidity was approximately $632 million, including $208 million in cash on hand.

Negatives

• Revenue decreased by 9% compared to the prior year.
• GAAP EPS decreased from $0.24 to $0.09.
• Adjusted EPS decreased by 19% compared to the prior year.
• Total backlog decreased 15% compared to the prior year.
• Adjusted EBITDA decreased 15% compared to the prior year.

Risks

• The company acknowledges the potential impacts of tariff policy and foreign currency exchange rate fluctuations.
• The outlook does not assume a broad-based recession, which could impact performance.
• The company faces risks related to global market and economic conditions, IT disruptions, labor shortages, and supply chain disruptions.
• There are risks associated with acquisitions, including the Schenck Process Food and Performance Materials (FPM) business and Linxis Group SAS (Linxis) acquisitions.
• The company is exposed to tax uncertainties and audits.

Future Outlook

Hillenbrand is updating its full-year revenue guidance to $2.625 $2.790 billion and adjusted EPS guidance to $2.45 $2.80, reflecting the sale of the Milacron business. Q2 revenue is expected to be $685 $705 million and adjusted EPS is expected to be $0.53 $0.58.

Management Comments

• 'We delivered first quarter results in line with our expectations, with continued momentum in executing cross-selling and cost synergies within our food, health, and nutrition portfolio,' said Kim Ryan, President and Chief Executive Officer of Hillenbrand.
• Kim Ryan also stated that the agreement to divest a majority stake in the Milacron business reflects the continuation of Hillenbrand's transformation towards less cyclical, higher-growth opportunities.

Industry Context

Hillenbrand's strategic shift towards food, health, and nutrition end markets reflects a broader trend of industrial companies seeking to diversify into more stable and growing sectors. The divestiture of Milacron aligns with this strategy, allowing Hillenbrand to focus on its core strengths and reduce exposure to cyclical industries.

Comparison to Industry Standards

• Comparable companies in the industrial sector, such as Illinois Tool Works (ITW) and Dover Corporation, often trade at higher multiples due to their diversified portfolios and strong cash flow generation.
• The sale of Milacron for $287 million, generating approximately $250 million in net proceeds, will be used for debt paydown, which is a common strategy among industrial companies to improve their financial flexibility.
• Hillenbrand's net debt to adjusted EBITDA ratio of 3.4x is within a reasonable range for industrial companies, but the company aims to deleverage further with the proceeds from the Milacron sale.

Stakeholder Impact

• Shareholders will see a shift in the company's portfolio towards less cyclical, higher-growth opportunities.
• Employees of Milacron will transition to new ownership under Bain Capital.
• Customers of Milacron will be served by a new ownership structure with Bain Capital's support.
• Suppliers may experience changes in their relationships with Milacron under new ownership.
• Creditors will benefit from the debt paydown using proceeds from the Milacron sale.

Next Steps

• Complete the sale of the majority stake in the Milacron business, expected by the end of Hillenbrand's fiscal second quarter or the beginning of the fiscal third quarter.
• Use the net proceeds from the Milacron sale for debt paydown.
• Continue to execute cross-selling and cost synergies within the food, health, and nutrition portfolio.
• Monitor the potential impacts of tariff policy and foreign currency exchange rate fluctuations.

Key Dates